United States Continuous Glucose Monitoring Market Size & Forecast 2025–2033

United States Continuous Glucose Monitoring Market Outlook

The United States Continuous Glucose Monitoring (CGM) Market is poised for robust expansion, projected to grow from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, registering a CAGR of 8.36% during the forecast period 2025–2033, according to Renub Research. This sustained growth is driven by the escalating prevalence of diabetes, rapid technological innovations in wearable medical devices, expanding insurance reimbursement, and a decisive shift toward proactive, data-driven chronic disease management.

Download Free Sample Report

In a healthcare ecosystem increasingly focused on prevention, personalization, and remote monitoring, CGM systems have transitioned from niche tools for Type 1 diabetes patients to mainstream solutions embraced by insulin-dependent Type 2 patients, hospitals, and homecare settings across the country.

United States Continuous Glucose Monitoring Market Overview

Continuous Glucose Monitoring (CGM) is an advanced diabetes management technology that tracks glucose levels in real time, day and night. Unlike traditional finger-stick testing—which provides only a single glucose reading—CGM systems use a small sensor placed beneath the skin to measure interstitial glucose continuously. This data is wirelessly transmitted to a receiver, smartphone, or smartwatch, enabling users and clinicians to monitor trends, fluctuations, and potential risks instantly.

In the United States, CGM adoption has accelerated dramatically over the past decade. Rising diabetes prevalence, combined with patient demand for convenience and improved outcomes, has made CGMs a cornerstone of modern diabetes care. Major players such as DexCom Inc., Abbott Laboratories, and Medtronic Plc. have transformed CGM devices into smaller, more accurate, and user-friendly systems with extended wear times and minimal calibration requirements.

Widening Medicare and private insurance coverage has further democratized access, while clinicians increasingly recommend CGMs to achieve tighter glycemic control, reduce hypoglycemia, and prevent long-term complications. Collectively, these trends underscore a nationwide transition toward continuous, connected, and patient-empowered diabetes management.

Key Growth Drivers Shaping the U.S. CGM Market

Rising Diabetes Prevalence and Early Diagnosis

The United States remains one of the largest diabetes markets globally, with over 38 million Americans living with the condition. Both Type 1 diabetes and insulin-dependent Type 2 diabetes continue to rise due to aging demographics, sedentary lifestyles, obesity, and dietary patterns. As awareness grows around the importance of early intervention and tight glycemic control, CGM systems are increasingly replacing intermittent glucose testing.

Healthcare providers recognize that continuous monitoring significantly reduces hospitalizations, acute glycemic events, and long-term complications such as neuropathy, retinopathy, and cardiovascular disease. Public awareness campaigns, improved screening programs, and preventive care initiatives are driving CGM adoption across pediatric, adult, and geriatric populations.

Technological Innovation and Wearable Integration

Rapid innovation is at the heart of the U.S. CGM market’s expansion. Modern CGM devices now offer factory-calibrated sensors, extended wear durations of up to 14 days, real-time alerts, and seamless smartphone connectivity. Integration with insulin pumps and digital health platforms allows for near-closed-loop or “artificial pancreas” systems that automate insulin delivery.

The popularity of health-tech wearables has also played a critical role. Tech-savvy consumers increasingly expect intuitive apps, cloud-based data sharing, and remote physician access. A notable milestone came in June 2024, when Abbott received FDA approval for two over-the-counter CGM systems—Lingo™ and Libre Rio™—signaling a shift toward broader consumer accessibility beyond prescription-only models.

Expanding Insurance Coverage and Policy Support

Insurance reimbursement has been a game changer for CGM adoption in the U.S. Medicare, Medicaid, and most commercial insurers now cover CGMs for a wider population, including patients on basal insulin therapy. The Centers for Medicare & Medicaid Services (CMS) have expanded eligibility criteria, significantly reducing financial barriers for older adults and low-income patients.

Additionally, post-COVID healthcare reforms emphasizing telehealth and remote patient monitoring have strengthened the role of CGMs in chronic disease management. Federal and state-level support for digital health solutions continues to reinforce CGM adoption across clinical and homecare environments.

Challenges Facing the United States CGM Market

High Upfront and Recurring Costs

Despite broader reimbursement, affordability remains a concern. The upfront cost of CGM devices—such as Dexcom G7 or FreeStyle Libre 3—combined with recurring sensor replacement expenses can deter uninsured or underinsured patients. Even among insured users, co-pays and deductibles may limit long-term adherence.

Without further price competition, subsidy expansion, or value-based reimbursement models, cost-related barriers may persist, particularly in underserved and rural communities.

User Compliance and Data Overload

While CGMs deliver a wealth of actionable data, not all patients are equipped to interpret or respond to continuous glucose insights. Alarm fatigue, skin irritation, sensor adhesion issues, and digital complexity can reduce compliance—especially among elderly or less tech-literate users.

Addressing these challenges will require improved patient education, simplified interfaces, and ongoing clinician support to ensure CGMs deliver sustained clinical and behavioral benefits.

Component-Wise Market Insights

United States Continuous Glucose Monitoring Sensors Market

Sensors form the backbone of CGM systems, responsible for detecting glucose levels beneath the skin. Advances in biocompatibility, miniaturization, and accuracy have significantly improved patient comfort and reliability. Factory-calibrated, disposable sensors with extended wear times dominate the U.S. market, particularly in homecare and outpatient settings.

As demand rises, manufacturers continue to refine sensor technology to enhance precision, durability, and interoperability with insulin pumps and mobile applications.

United States Continuous Glucose Monitoring Transmitters Market

Transmitters relay glucose data from the sensor to receivers, smartphones, or insulin pumps. The market is shifting toward compact, Bluetooth-enabled transmitters with longer battery life and reusable designs. These innovations lower long-term costs while enabling real-time data sharing with clinicians and caregivers.

Transmitters also play a crucial role in telehealth integration, supporting remote consultations and personalized treatment adjustments.

End-User Insights

United States Continuous Glucose Monitoring Hospitals Market

Hospitals across the U.S. increasingly deploy CGMs for inpatient diabetes management, post-operative monitoring, and critical care. Real-time alerts help prevent hypoglycemia and hyperglycemia, reducing nurse workload and improving patient safety. During the COVID-19 pandemic, CGMs proved especially valuable for minimizing staff exposure while maintaining glycemic control in ICU settings.

As hospital protocols evolve, CGMs are becoming standard tools for enhancing efficiency and outcomes in acute care environments.

State-Level Market Highlights

California Continuous Glucose Monitoring Market

California leads the U.S. CGM market, driven by high diabetes prevalence, strong digital health infrastructure, and the presence of leading med-tech innovators. Tech-forward consumers, favorable insurance coverage, and public-private collaborations continue to boost statewide adoption.

New York Continuous Glucose Monitoring Market

New York’s diverse population and advanced healthcare system support rapid CGM uptake. Public health initiatives targeting early diagnosis and digital care integration are expanding access, particularly in urban and underserved communities.

New Jersey Continuous Glucose Monitoring Market

With a dense concentration of healthcare facilities and pharmaceutical companies, New Jersey demonstrates strong CGM adoption. Remote monitoring solutions and supportive reimbursement policies further enhance market growth.

Washington Continuous Glucose Monitoring Market

Washington State’s emphasis on digital health innovation and chronic disease management positions it as a key CGM growth market. Efforts to reduce healthcare disparities have improved access for rural and minority populations.

Market Segmentation Overview

By Component

Sensors

Transmitters

Receivers

By End User

Hospitals

Homecare Settings

Others

Top 10 States

California

Texas

New York

Florida

Illinois

Pennsylvania

Ohio

Georgia

Washington

New Jersey

Rest of United States

Competitive Landscape: Key Players Covered (5 Viewpoints Each)

Abbott Laboratories

Roche

Tandem Diabetes Care

DexCom Inc.

Senseonics Holdings Inc.

Ypsomed Holding AG

Medtronic Plc.

i-Sens Inc.

Each company analysis includes: Overview, Key Person, Recent Developments, SWOT Analysis, Revenue Analysis, and Strategic Outlook.

Final Thoughts

The United States Continuous Glucose Monitoring Market is entering a transformative phase. With strong backing from technological innovation, policy support, and rising patient awareness, CGMs are redefining how diabetes is managed across clinical and homecare settings. As affordability improves and user experience continues to evolve, CGM adoption is set to expand beyond high-risk patients to a broader consumer base.

By 2033, CGMs will not only be monitoring glucose—they will be shaping a smarter, more connected, and preventive healthcare ecosystem in the United States.